OptiNose, Inc. (NASDAQ:OPTN) Q2 2024 Results Conference Call August 8, 2024 8:00 AM ET
Company Participants
Jonathan Neely - VP, IR & Business Development
Dr. Ramy Mahmoud - CEO
Paul Spence - Chief Commercial Officer
Conference Call Participants
Schuyler van den Broek - Piper Sandler
Thomas Flaten - Lake Street Capital Markets
Operator
Hello, and welcome to the OptiNose Second Quarter 2024 Earnings Conference Call. At this time, all participants are in a listen-only mode. After the speakers’ presentation, there will be a question-and-answer session. [Operator Instructions] Please be advised that today's conference is being recorded.
It is now my pleasure to introduce Vice President of Investor Relations, Jonathan Neely.
Jonathan Neely
Good morning. Thank you for joining us today as we review OptiNose's second quarter 2024 performance and our plans for the remainder of the year. I'm joined today by: our CEO, Dr. Ramy Mahmoud; and our Chief Commercial Officer, Paul Spence. Slides that will be presented on this call can be viewed on our website optinose.com in the Investors section.
Before we start, I would like to remind you that our discussions during this conference call will include forward-looking statements. All statements that are not historical facts are hereby identified as forward-looking statements. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from those indicated in such statements.
Additional information regarding these factors and forward-looking statements is discussed under the Cautionary Note on Forward-Looking Statements section of the earnings release that we issued today as well as under the Risk Factors section and elsewhere in OptiNose's most recent Form 10-K and 10-Q that are filed with the SEC and available at their website, sec.gov and our website at optinose.com. You are cautioned not to place undue reliance on forward-looking statements. Forward-looking statements during this conference call speak only as of the original date of this call or any earlier date indicated in such statement, and we undertake no obligation to update or revise any of these statements.
We will now make prepared remarks, and then we will move to a question-and-answer session. With that, I will now turn the call over to Ramy.
Dr. Ramy Mahmoud
Thank you, Jonathan, and thank you to everyone listening for joining us this morning. We appreciate you joining us for our second quarter 2024 update.
Starting on Slide 3. We're pleased to report a promising start to our chronic sinusitis launch and good progress in the quarter. I'll start with a brief outline of what we'll cover during our call today. First, I'll review three key takeaways from today's call. Second, our Chief Commercial Officer, Paul Spence, will discuss our early efforts to educate our ENT and Allergy Specialist physician audience on XHANCE's new clinical profile and some encouraging early signals of progress that will enable future uptake. Next, Jonathan Neely, our VP of Investor Relations and Business Development, will review our second quarter 2024 performance and our financial guidance for full year 2024. Finally, we'll return to wrap up the call and take your questions.